Published in Am J Respir Crit Care Med on February 04, 2011
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54
Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med (2011) 1.41
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics (2013) 1.38
Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res (2012) 1.37
Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS One (2013) 1.26
Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ Heart Fail (2012) 1.23
A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol (2012) 1.18
The role of redox signaling in epigenetics and cardiovascular disease. Antioxid Redox Signal (2013) 1.03
Mitochondria and Oxidative Stress in the Cardiorenal Metabolic Syndrome. Cardiorenal Med (2012) 0.98
Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change. Pulm Circ (2012) 0.94
A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? Pulm Circ (2013) 0.94
Right ventricular adaptation and failure in pulmonary arterial hypertension. Can J Cardiol (2015) 0.94
Epigenetic mechanisms of pulmonary hypertension. Pulm Circ (2011) 0.93
Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ (2013) 0.90
Mechanical regulation of epigenetics in vascular biology and pathobiology. J Cell Mol Med (2013) 0.88
Novel therapeutic approaches to preserve the right ventricle. Curr Heart Fail Rep (2013) 0.88
Pulmonary artery smooth muscle cell proliferation and migration in fetal lambs acclimatized to high-altitude long-term hypoxia: role of histone acetylation. Am J Physiol Lung Cell Mol Physiol (2012) 0.87
Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension. Exp Mol Med (2015) 0.87
Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders. Pharmacol Rev (2016) 0.87
Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension. Circulation (2014) 0.86
Epigenetic modifications: basic mechanisms and role in cardiovascular disease (2013 Grover Conference series). Pulm Circ (2014) 0.86
Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med (2016) 0.84
Epigenetics within the matrix: a neo-regulator of fibrotic disease. Epigenetics (2012) 0.83
Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series). Pulm Circ (2014) 0.82
Potential non-oncological applications of histone deacetylase inhibitors. Am J Transl Res (2011) 0.82
Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy. Biochem Cell Biol (2014) 0.81
MLL histone methylases regulate expression of HDLR-SR-B1 in presence of estrogen and control plasma cholesterol in vivo. Mol Endocrinol (2012) 0.80
Right ventricular failure and pathobiology in patients with congenital heart disease - implications for long-term follow-up. Front Pediatr (2013) 0.80
Molecular pathogenesis and current pathology of pulmonary hypertension. Heart Fail Rev (2016) 0.80
Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series). Pulm Circ (2015) 0.79
Human GRK4γ142V Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition. Hypertension (2015) 0.79
Pressure-overload-induced right heart failure. Pflugers Arch (2014) 0.78
Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. Biomed Res Int (2015) 0.78
Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol (2016) 0.77
Right Ventricular Myocardial Stiffness in Experimental Pulmonary Arterial Hypertension: Relative Contribution of Fibrosis and Myofibril Stiffness. Circ Heart Fail (2016) 0.77
The emerging role of epigenetics in pulmonary arterial hypertension: an important avenue for clinical trials (2015 Grover Conference Series). Pulm Circ (2016) 0.76
Right ventricular failure due to chronic pressure load: What have we learned in animal models since the NIH working group statement? Heart Fail Rev (2015) 0.76
Epigenetic Regulation of Interleukin 6 by Histone Acetylation in Macrophages and Its Role in Paraquat-Induced Pulmonary Fibrosis. Front Immunol (2017) 0.76
Integrating molecular genetics and systems approaches to pulmonary vascular diseases. Pulm Circ (2013) 0.75
Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Future Cardiol (2013) 0.75
Novel putative pharmacologic therapies to protect the right ventricle in pulmonary hypertension: A review of current literature. Br J Pharmacol (2017) 0.75
The cancer theory of pulmonary arterial hypertension. Pulm Circ (2017) 0.75
Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 5.79
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol (2009) 3.75
The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 3.09
Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2007) 3.06
Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol (2007) 3.05
Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med (2003) 3.00
The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest (2009) 2.92
Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation (2009) 2.73
Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol (2003) 2.59
Targeting interleukin-1 in heart disease. Circulation (2013) 2.52
Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation (2010) 2.43
HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol (2005) 2.43
An animal model of autoimmune emphysema. Am J Respir Crit Care Med (2004) 2.40
Pressure support improves oxygenation and lung protection compared to pressure-controlled ventilation and is further improved by random variation of pressure support. Crit Care Med (2011) 2.34
Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J (2005) 2.33
Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ (2013) 2.26
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol (2010) 2.23
A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J (2006) 2.22
Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. Am J Respir Crit Care Med (2004) 2.22
Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol (2009) 2.21
Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med (2010) 2.20
Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res (2007) 2.19
A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol (2008) 2.17
Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med (2008) 2.08
Molecular pathogenesis of emphysema. J Clin Invest (2008) 2.03
Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res (2003) 2.00
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 1.92
Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury. J Am Soc Nephrol (2006) 1.88
Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol (2008) 1.86
Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med (2003) 1.85
Comparative effects of proportional assist and variable pressure support ventilation on lung function and damage in experimental lung injury. Crit Care Med (2012) 1.83
Apoptosis and emphysema: the missing link. Am J Respir Cell Mol Biol (2003) 1.82
The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A (2011) 1.81
Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion (2003) 1.79
Cirrhotic cardiomyopathy. J Am Coll Cardiol (2010) 1.77
Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res (2005) 1.76
Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. FASEB J (2004) 1.74
Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J (2005) 1.74
Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol (2002) 1.73
A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med (2006) 1.72
Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J (2005) 1.72
Selective serotonin reuptake inhibitors provide significant lower re-hospitalization rates in patients recovering from acute coronary syndromes: evidence from a meta-analysis. J Psychopharmacol (2009) 1.70
Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury. Crit Care Med (2011) 1.68
Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. Atherosclerosis (2012) 1.63
Apoptosis and post-infarction left ventricular remodeling. J Mol Cell Cardiol (2002) 1.63
HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med (2006) 1.58
The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol (2011) 1.54
Emphysema lung tissue gene expression profiling. Am J Respir Cell Mol Biol (2004) 1.49
Higher levels of spontaneous breathing reduce lung injury in experimental moderate acute respiratory distress syndrome. Crit Care Med (2014) 1.47
Pulmonary blood flow increases in damaged regions directly after acid aspiration in rats. Anesthesiology (2013) 1.45
AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. J Leukoc Biol (2009) 1.45
Late percutaneous coronary intervention for the totally occluded infarct-related artery: a meta-analysis of the effects on cardiac function and remodeling. Catheter Cardiovasc Interv (2008) 1.44
Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med (2007) 1.42
Effects of intravascular volume replacement on lung and kidney function and damage in nonseptic experimental lung injury. Anesthesiology (2013) 1.42
HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol (2005) 1.42
The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. Breast Cancer Res Treat (2009) 1.41
Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation (2009) 1.40
Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2004) 1.40
Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J (2012) 1.39
Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. J Clin Invest (2007) 1.38
Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol (2011) 1.36
Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res (2009) 1.35
Adenovirus-mediated HIF-1α gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. J Clin Invest (2011) 1.35
Deoxycholic acid activates the c-Jun N-terminal kinase pathway via FAS receptor activation in primary hepatocytes. Role of acidic sphingomyelinase-mediated ceramide generation in FAS receptor activation. J Biol Chem (2003) 1.33
Reversible or irreversible remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol (2009) 1.33
Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res (2011) 1.31
Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med (2005) 1.30
Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2006) 1.30
Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol (2010) 1.28
Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest (2006) 1.28
Variable tidal volumes improve lung protective ventilation strategies in experimental lung injury. Am J Respir Crit Care Med (2009) 1.27
Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol (2013) 1.26
Sex-related differences in myocardial remodeling. J Am Coll Cardiol (2010) 1.25
p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am J Physiol Lung Cell Mol Physiol (2011) 1.24
Activation of tubular epithelial cells in diabetic nephropathy. Diabetes (2002) 1.24
Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol (2011) 1.23